Skip to main content
Premium Trial:

Request an Annual Quote

GenMark to Net $39.3M from Public Offering

NEW YORK (GenomeWeb News) – GenMark Diagnostics late on Wednesday priced its public offering of 10 million shares at $4.20 per share.

The offering, which was announced on Tuesday, is expected to close on June 26. The firm expects to raise net proceeds of $39.3 million.

Those funds will go toward R&D work to expand the Carlsbad, Calif.-based molecular diagnostic firm's test menu and to further develop its NexGen System, a sample-to-answer platform. It will also be used to expand the company's US and global commercialization operations.

JP Morgan is the sole book-running manager on the offering. William Blair & Co. and Canaccord Genuity are co-managers. The underwriters have a 30-day option to purchase up to an additional 1.5 million shares to cover any over-allotments.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.